Study to find incidence of residual neuromuscular paralysis by using neuromuscular monitor after various doses of neostigmine reversal agent

Study of cisatracurium induced neuromuscular block reversal with different doses of neostigmine and incidence of residual neuromuscular paralysis by using neuromuscular monitor

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/08/027270

Enrollment

180

Registered

2020-08-20

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M00-M99- Diseases of the musculoskeletal system and connective tissue

Interventions

Intervention1: neuromuscular monitoring after neuromuscular relaxant: Train of Four monitoring during reversal of neuromuscular blockade in 2020-21 Control Intervention1: NEUROMUSCULAR MONITORING AFTE

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients willing to participate in the study. 2.Age group between 20 - 40 years. 3.Weight of the patient between 40-70Kgs. 4.Patients belonging to ASA class-I and II

Exclusion criteria

Exclusion criteria: 1.Obesity (BMI >= 35). 2.Patients with abnormal airway (Mallampati score 3 or more). 3.History of any known neuromuscular disease. 4.Patients with any known cardiac/ respiratory / hepatic or renal disease 5.Patients with known allergy to any drug used in study. 6.Patients taking medication that influences neuromuscular blockade

Design outcomes

Primary

Measure	Time frame
To find out the optimum dose of neostigmine for reversal of cisatracurium induced neuromuscular block of different intensity by using neuromuscular monitor (TOF).Timepoint: At baseline when patient is recovering from anesthesia after completion of surgery	—

Countries

India

Contacts

Public ContactYogesh Chand Modi

SMS Medical College

rajesh_sms@hotmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026